Adherence to New Oral Anticoagulation Therapy in Turkey (NOAC-TR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02480920|
Recruitment Status : Completed
First Posted : June 25, 2015
Last Update Posted : July 26, 2016
|Condition or disease|
NOACs have several clinical and pharmacological advantages over warfarin however suboptimal adherence is one of the most common causes of failure to respond to medications and outcomes.
This observational multicenter, retrospective study, will compose a national database of drug adherence and investigate the factors that affect drug adherence in patients taking new oral anticoagulation therapy in Turkey.
Social support and adherence to therapy factors that may affect drug adherence and adverse events will be assessed by self-report questionnaires.
Non-adherence will be tested for demographic, clinical, awareness of NOAC therapy and socioeconomic factors.
|Study Type :||Observational|
|Actual Enrollment :||2734 participants|
|Official Title:||Drug Adherence in Patients Taking New Oral Anticoagulation Therapy in Turkey|
|Study Start Date :||July 2015|
|Actual Primary Completion Date :||March 2016|
|Actual Study Completion Date :||April 2016|
- Compliance of NOACs in Turkish Population [ Time Frame: 10 months ]Factors that may affect drug adherence and adverse events will be assessed by self-report questionnaires. Non-adherence will be tested for demographic, clinical, awareness of NOAC therapy and socioeconomic factors.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02480920
|Principal Investigator:||Volkan Emren, MD||Cardiovascular Academy Society, İzmir, Turkey|